Lannett Announces Submission Of Investigational New Drug Application For Biosimilar Insulin Glargine
Lannett Company, Inc. (NYSE:LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin